Families research, compare and consult across 3 or 4 institutions before committing. Campaigns optimised for same-session conversion measure almost none of that, and cost per lead improves while cases are lost.
An adult child, a spouse or a referring physician is usually the one comparing institutions. Content written to reassure a patient often fails the person actually making the shortlist.
The institution that returns a records review quickly, with a named clinician attached, tends to win. That is an operational commitment, not a creative one, and it sits outside the scope of most marketing engagements.
International and out-of-state families abandon over visas, travel, accommodation, duration of stay and who coordinates it. These questions are unanswered on most oncology websites, so the enquiry ends before clinical capability is ever assessed.
Oncology rewards named clinical authority far more than institutional brand. A sub-specialist with a visible, attributable body of work is easier for both a family and an answer engine to evaluate than a hospital name alone.
We build discoverable, attributable profiles for named oncologists by sub-specialty, because that is the level at which second-opinion searches actually happen. upGrowth works with Dr. Aditya Sarin, medical oncologist at Sir Ganga Ram Hospital, New Delhi, on exactly this.
Content mapped to the real sequence a family moves through: what a second opinion involves, what records are needed, how long a review takes, and what happens next. Practical, not promotional.
Health queries attract the strictest source selection of any category in AI answers. We build the attribution, sourcing and entity signals that make an oncology programme quotable rather than skipped.
Visa guidance, travel and stay duration, coordinator contact and cost structure, published rather than promised on a call. This is where cross-border enquiries are won or lost.
Referring physicians are an audience with their own evaluation criteria, their own channels and their own timeline. We treat them as a distinct acquisition motion rather than a relationship exercise.
Timestamps from enquiry received to records requested, records received to clinician response, and response to consultation booked. Without these the funnel is unmeasurable past the form.
Most healthcare marketing assumes a decision that resolves in one visit. Oncology does not. The patient may never be the person reading your website, the enquiry often arrives from another state or another country, and the deciding factor is usually how fast a named clinician responds to a records review rather than anything in your campaign. We plan oncology acquisition as a multi-week, multi-person decision with a defined owner at every step.
Sub-specialty search visibility and second-opinion journey content built for a researching family.
Presence inside AI-generated answers, where an increasing share of health research now begins.
Named, attributable expertise for individual oncologists across owned and third-party surfaces.
Logistics-first content and enquiry handling for cross-border and out-of-state families.
A distinct motion aimed at referring physicians, with its own funnel and reporting.
Measurement from enquiry to records to clinician response to consultation, replacing cost per lead.
Survival figures, success rates and comparative efficacy cannot be used in marketing. Any oncology strategy that depends on outcome claims is unworkable before it starts, and the strongest programmes are built on process transparency instead.
Patient testimonials in oncology are both regulated and ethically fraught. We build credibility through named clinical expertise and published process rather than through patient stories.
Health targeting restrictions limit audience building and remarketing. Platform policy changes without notice, so current policy must be checked directly before any campaign, and channel concentration is a business risk.
An oncology enquiry that never becomes a consultation still counts as a lead. Reporting that stops at the form will show improvement while the department loses cases.
We work with oncology clinicians and healthcare organisations on visibility, patient acquisition and AI search presence. Our work in this specialty is built on making named clinical expertise legible and attributable rather than on claims we are not permitted to make.
Acquisition designed for a decision that runs weeks and involves several people, with measurement that survives past the first touch.
We work with individual oncologists on discoverable, attributable expertise. upGrowth’s work with Dr. Aditya Sarin is built on that principle.
We run India patient acquisition for HELENE Clinic, Tokyo, so the international enquiry path is something we work on directly rather than theoretically.
Generative engine optimisation runs as a named service here, not as an add-on to search. Health carries the strictest source selection of any category in AI answers, so the sourcing, attribution and entity work has to be deliberate to be quoted at all.
The metric is the problem. Oncology is judged on cost per lead in most hospitals, and cost per lead cannot see a decision that takes 3 weeks and involves 4 institutions. A department can report improving lead costs across a quarter in which it lost every case it competed for.
The metric that works is cost per consultation attended, split by enquiry origin, with the time from records received to named clinician response reported alongside it. That second number is usually the one that moves the outcome, and it is almost never on a marketing dashboard because it belongs to operations.
Our series on healthcare growth covers the mechanism in detail in Pain in the Diagnosis.